Health Care & Life Sciences » Pharmaceuticals | Mitsubishi Tanabe Pharma Corp.

Mitsubishi Tanabe Pharma Corp. | Ownership

Companies that own Mitsubishi Tanabe Pharma Corp.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BlackRock Fund Advisors
7,009,800
1.25%
30,600
0.01%
09/06/2018
The Vanguard Group, Inc.
6,023,457
1.07%
107,500
0%
07/31/2018
Nomura Asset Management Co., Ltd.
5,196,199
0.93%
-8,423
0.05%
07/31/2018
Norges Bank Investment Management
4,347,299
0.77%
-113,346
0.01%
12/31/2017
APG Asset Management NV
2,452,398
0.44%
-1,364,463
0.03%
03/31/2018
Daiwa Asset Management Co. Ltd.
2,224,300
0.4%
-93,600
0.04%
07/31/2018
Nikko Asset Management Co., Ltd.
2,110,097
0.38%
105,197
0.02%
09/03/2018
BNY Mellon Asset Management North America Corp.
1,841,627
0.33%
0
0.02%
09/07/2018
ValueInvest Asset Management SA
1,559,300
0.28%
-33,300
0.55%
08/31/2018
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.
1,336,400
0.24%
-1,102,500
0.05%
01/22/2018

About Mitsubishi Tanabe Pharma

View Profile
Address
3-2-10 Dosho-machi
Osaka Osaka 541
Japan
Employees -
Website http://www.mt-pharma.co.jp
Updated 07/08/2019
Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. The company operates through Pharmaceuticals segment.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.